Prophylactic Versus Reactive Megestrol Acetate Use for Critical Body Weight Loss in Patients with Pharyngeal and Laryngeal Squamous Cell Carcinoma Undergoing Concurrent Chemoradiotherapy

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Le Maitre A, Maillard E, Bourhis J, Group M-NC, MACH-NC Collaborative Group Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14. doi: 10.1016/j.radonc.2009.04.014.
   PubMed Web of Science ®Google Scholar
• Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8(7):613–24. doi: 10.1016/S1470-2045(07)70144-4.
   PubMed Web of Science ®Google Scholar
• Jager-Wittenaar H, Dijkstra PU, Vissink A, van der Laan BFAM, van Oort RP, Roodenburg JLN. Critical weight loss in head and neck cancer–prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer. 2007;15(9):1045–50. doi: 10.1007/s00520-006-0212-9.
   PubMed Web of Science ®Google Scholar
• Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Barnes CA, Gourin CG, Der-Torossian H. Cancer cachexia update in head and neck cancer: definitions and diagnostic features. Head Neck. 2015;37(4):594–604. doi: 10.1002/hed.23599.
   PubMed Web of Science ®Google Scholar
• Silander E, Nyman J, Bove M, Johansson L, Larsson S, Hammerlid E. Impact of prophylactic percutaneous endoscopic gastrostomy on malnutrition and quality of life in patients with head and neck cancer: a randomized study. Head Neck. 2012;34(1):1–9. doi: 10.1002/hed.21700.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi: 10.1016/S1470-2045(10)70218-7.
   PubMed Web of Science ®Google Scholar
• Langius JAE, Bakker S, Rietveld DHF, Kruizenga HM, Langendijk JA, Weijs PJM, Leemans CR. Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy. Br J Cancer. 2013;109(5):1093–9. doi: 10.1038/bjc.2013.458.
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Hayoz S, Zimmermann F, Bodis S, Kaul D, Badakhshi H, Bernier J, Studer G, Plasswilm L, Budach V, et al. Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol. 2015;10(1):21. doi: 10.1186/s13014-014-0319-y.
   PubMedGoogle Scholar
• Hung C-Y, Hsueh S-W, Lu C-H, Chang P-H, Chen P-T, Yeh K-Y, Wang H-M, Tsang N-M, Huang P-W, Hung Y-S, et al. A prospective nutritional assessment using Mini Nutritional Assessment-short form among patients with head and neck cancer receiving concurrent chemoradiotherapy. Support Care Cancer. 2021;29(3):1509–18. doi: 10.1007/s00520-020-05634-3.
   PubMed Web of Science ®Google Scholar
• Singh GK, Patil VM, Noronha V, Joshi A, Menon N, Lashkar SG, Mathrudev V, Satam KN, Prabhash K. Weight loss and its impact on outcome in head and cancer patients during chemo-radiation. Oral Oncol. 2021;122:105522. doi: 10.1016/j.oraloncology.2021.105522.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Sato Y, Fujiwara Y, Fukuda N, Wang X, Nakano K, Urasaki T, Ohmoto A, Ono M, Tomomatsu J, et al. Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy. Cancer Manag Res. 2021;13:8377–85. doi: 10.2147/CMAR.S329581.
   PubMed Web of Science ®Google Scholar
• Wang CH, Wang HM, Pang YP, Yeh KY. Early nutritional support in non-metastatic stage IV oral cavity cancer patients undergoing adjuvant concurrent chemoradiotherapy: analysis of treatment tolerance and outcome in an area endemic for betel quid chewing. Support Care Cancer. 2012;20(6):1169–74. doi: 10.1007/s00520-011-1192-y.
   PubMed Web of Science ®Google Scholar
• Ho Y-W, Yeh K-Y, Hsueh S-W, Hung C-Y, Lu C-H, Tsang N-M, Wang H-M, Hung Y-S, Chou W-C. Impact of early nutrition counseling in head and neck cancer patients with normal nutritional status. Support Care Cancer. 2021;29(5):2777–85. doi: 10.1007/s00520-020-05804-3.
   PubMed Web of Science ®Google Scholar
• Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, et al. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol. 1999;17(1):64–73. doi: 10.1200/JCO.1999.17.1.64.
   PubMed Web of Science ®Google Scholar
• Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Marti S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;2013(3):CD004310. doi: 10.1002/14651858.CD004310.pub3.
   PubMed Web of Science ®Google Scholar
• Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Hsu JH. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiother Oncol. 1997;43(1):75–9. doi: 10.1016/s0167-8140(97)01921-x.
   PubMed Web of Science ®Google Scholar
• Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R. Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. Eur J Cancer. 1997;33(1):75–9. doi: 10.1016/s0959-8049(96)00309-7.
   PubMed Web of Science ®Google Scholar
• McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, Shaw EG. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2002;52(5):1180–5. doi: 10.1016/s0360-3016(01)02782-1.
   PubMed Web of Science ®Google Scholar
• Capuano G, Grosso A, Gentile PC, Battista M, Bianciardi F, Di Palma A, Pavese I, Satta F, Tosti M, Palladino A, et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck. 2008;30(4):503–8. doi: 10.1002/hed.20737.
   PubMed Web of Science ®Google Scholar
• Huang P-W, Lin C-Y, Hsieh C-H, Hsu C-L, Fan K-H, Huang S-F, Liao C-T, Ng S-K, Yen T-C, Chang JT-C, et al. A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. Biomed J. 2018;41(2):129–36. doi: 10.1016/j.bj.2018.04.003.
   PubMed Web of Science ®Google Scholar
• Wang H-M, Hsueh C-T, Wang C-S, Chen I-H, Liao C-T, Tsai M-H, Yeh S-P, Chang JT-C. Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx. Anticancer Drugs. 2005;16(4):447–53. doi: 10.1097/00001813-200504000-00012.
   PubMed Web of Science ®Google Scholar
• Simons JP, Aaronson NK, Vansteenkiste JF, ten Velde GP, Muller MJ, Drenth BM, Erdkamp FL, Cobben EG, Schoon EJ, Smeets JB, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol. 1996;14(4):1077–84. doi: 10.1200/JCO.1996.14.4.1077.
   PubMed Web of Science ®Google Scholar
• Rowland KM, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, Kugler JW, Tschetter LK, Ghosh C, Schaefer PL, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996;14(1):135–41. doi: 10.1200/JCO.1996.14.1.135.
   PubMed Web of Science ®Google Scholar
• McClelland S, 3rd, Andrews JZ, Chaudhry H, Teckie S, Goenka A. Prophylactic versus reactive gastrostomy tube placement in advanced head and neck cancer treated with definitive chemoradiotherapy: a systematic review. Oral Oncol. 2018;87:77–81. doi: 10.1016/j.oraloncology.2018.10.028.
   PubMed Web of Science ®Google Scholar
• Platek ME, Myrick E, McCloskey SA, Gupta V, Reid ME, Wilding GE, Cohan D, Arshad H, Rigual NR, Hicks WL, et al. Pretreatment weight status and weight loss among head and neck cancer patients receiving definitive concurrent chemoradiation therapy: implications for nutrition integrated treatment pathways. Support Care Cancer. 2013;21(10):2825–33. doi: 10.1007/s00520-013-1861-0.
   PubMed Web of Science ®Google Scholar
• Luan C-W, Tsai Y-T, Yang H-Y, Chen K-Y, Chen P-H, Chou H-H. Pretreatment prognostic nutritional index as a prognostic marker in head and neck cancer: a systematic review and meta-analysis. Sci Rep. 2021;11(1):17117. doi: 10.1038/s41598-021-96598-9.
   PubMed Web of Science ®Google Scholar
• Coca-Pelaz A, Rodrigo JP, Suárez C, Nixon IJ, Mäkitie A, Sanabria A, Quer M, Strojan P, Bradford CR, Kowalski LP, et al. The risk of second primary tumors in head and neck cancer: a systematic review. Head Neck. 2020;42(3):456–66. doi: 10.1002/hed.26016.
   PubMed Web of Science ®Google Scholar
• Rose BS, Jeong JH, Nath SK, Lu SM, Mell LK. Population-based study of competing mortality in head and neck cancer. J Clin Oncol. 2011;29(26):3503–9. doi: 10.1200/JCO.2011.35.7301.
   PubMed Web of Science ®Google Scholar
• Massa ST, Osazuwa-Peters N, Christopher KM, Arnold LD, Schootman M, Walker RJ, Varvares MA. Competing causes of death in the head and neck cancer population. Oral Oncol. 2017;65:8–15. doi: 10.1016/j.oraloncology.2016.12.006.
   PubMed Web of Science ®Google Scholar
• Santos EW, Oliveira DC, Silva GB, Tsujita M, Beltran JO, Hastreiter A, Fock RA, Borelli P. Hematological alterations in protein malnutrition. Nutr Rev. 2017;75(11):909–19. doi: 10.1093/nutrit/nux041.
   PubMed Web of Science ®Google Scholar
• De Filippo E, Marra M, Alfinito F, Di Guglielmo ML, Majorano P, Cerciello G, De Caprio C, Contaldo F, Pasanisi F. Hematological complications in anorexia nervosa. Eur J Clin Nutr. 2016;70(11):1305–8. doi: 10.1038/ejcn.2016.115.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol. 2007;25(26):4096–103. doi: 10.1200/JCO.2007.13.3983.
   PubMed Web of Science ®Google Scholar
• Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277–84. doi: 10.1038/nrc1318.
   PubMed Web of Science ®Google Scholar
• Couch ME, Dittus K, Toth MJ, Willis MS, Guttridge DC, George JR, Chang EY, Gourin CG, Der-Torossian H. Cancer cachexia update in head and neck cancer: pathophysiology and treatment. Head Neck. 2015;37(7):1057–72. doi: 10.1002/hed.23696.
   PubMed Web of Science ®Google Scholar
• Siddiqui JA, Pothuraju R, Jain M, Batra SK, Nasser MW. Advances in cancer cachexia: intersection between affected organs, mediators, and pharmacological interventions. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188359. doi: 10.1016/j.bbcan.2020.188359.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Massa E, Dessì D, Melis GB, Del Giacco GS. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer. 1997;33(4):602–7. doi: 10.1016/s0959-8049(96)00486-8.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol. 1998;25(2 Suppl 6):45–52.
   PubMed Web of Science ®Google Scholar
• de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15. doi: 10.1016/S1470-2045(12)70137-7.
   PubMed Web of Science ®Google Scholar
• Hwang TZ, Hsiao JR, Tsai CR, Chang JS. Incidence trends of human papillomavirus-related head and neck cancer in Taiwan, 1995-2009. Int J Cancer. 2015;137(2):395–408. doi: 10.1002/ijc.29330.
   PubMed Web of Science ®Google Scholar